Kura reports phase 1a trial results for kidney cancer treatment
SAN DIEGO - Kura Oncology, Inc. (NASDAQ:KURA) announced results from its Phase 1a FIT-001 clinical trial evaluating darlifarnib combined with cabozantinib in patients with advanced clear cell renal cell carcinoma, according to a press release statement.
Reported by 1 outlet — Investing.com · Company News. See all sources ↓
SAN DIEGO - Kura Oncology, Inc. (NASDAQ:KURA) announced results from its Phase 1a FIT-001 clinical trial evaluating darlifarnib combined with cabozantinib in patients with advanced clear cell renal cell carcinoma, according to a press release statement. The trial enrolled 34 cabozantinib-naïve patients with locally advanced or metastatic clear cell renal cell carcinoma who had received prior treatment. Objective response rates ranged from 33% to 50% across different darlifarnib dose levels.
Read the full report at Investing.com · Company News ↗
Why it matters
A world story we're tracking; its significance and source trust firm up as more outlets confirm it.
- What's the story?
- SAN DIEGO - Kura Oncology, Inc. (NASDAQ:KURA) announced results from its Phase 1a FIT-001 clinical trial evaluating darlifarnib combined with cabozantinib in patients with advanced clear cell renal cell carcinoma, according to a press release statement.
- How widely is it covered?
- 1 outlet, average source rating 5.0/10.
- When was it last updated?
- 2m ago.
How outlets are framing the same story
Here's how each outlet is covering the story — compare their headlines and timing at a glance.
- Coverage card1 outlet1CoverageScouting report
Kura reports phase 1a trial results for kidney cancer treatment
Sources1TypeCoverageInvesting.com · Company News